RA
ABEO icon

Rosalind Advisors’s Abeona Therapeutics ABEO Stock Holding History

Rosalind Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,805,817
Closed -$8.6M – 38
2025
Q1 		$8.6M Buy
1,805,817
+427
+0% +$2.32K 4.18% 9
2024
Q4 		$10.1M Sell
1,805,390
-26,610
-1% -$164K 5.14% 6
2024
Q3 		$11.6M Buy
1,832,000
+82,000
+5% +$428K 7.41% 4
2024
Q2 		$7.42M Buy
+1,750,000
New +$8.93M 5.71% 5

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BCM
Boone Capital Management Atlanta, Georgia $428M AUM 136.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Rosalind Advisors's ABEO Position: Q2 2025 in Review

Rosalind Advisors sold out of Abeona Therapeutics (ABEO) in Q2 2025, closing a stake of 1,805,817 shares — an estimated $8.6M sold.

Rosalind Advisors first reported a position in ABEO in Q2 2024 and held it in 4 quarters. The position peaked at $11.6M in Q3 2024. 95 funds tracked by Wall St. Rank hold ABEO as of Q2 2025.

  • Rosalind Advisors reported no remaining Abeona Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Rosalind Advisors sold 1,805,817 Abeona Therapeutics shares in Q2 2025, an estimated $8.6M.
  • Rosalind Advisors first reported a position in Abeona Therapeutics in Q2 2024 and held it in 4 quarters.
  • Rosalind Advisors's Abeona Therapeutics position peaked at $11.6M in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2025.

Based on Rosalind Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.